FDA Approved: DOPTELET — Supplemental Application (AkaRx, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DOPTELET (avatrombopag maleate) from AkaRx, Inc., likely expanding labeling or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Liver Disease

Drugs mentioned

• DOPTELET (avatrombopag)

Snippet

SUPPL AP for DOPTELET (AVATROMBOPAG MALEATE)